RNS
Reach - non-regulatory announcement
18 December
2024
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Proactive Investors
interviews with CEO and Chairman
Graft Polymer, an innovative
biotechnology company co-developing therapeutics for mental health
disorders, announces interviews on Proactive Investors with
Anthony Tennyson, CEO and Dennis Purcell, Chairman. The interview
with Anthony Tennyson can we viewed now at
https://www.proactiveinvestors.co.uk/LON:GPL/Graft-Polymer-UK-PLC
and the interview with Dennis Purcell will be
available from this Thursday, 19 December 2024.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk
Allenby Capital (Financial Adviser and Broker)
+44 (0) 20 3328 5656
Nick Naylor
/ Liz Kirchner (Corporate Finance) | Guy McDougall
(Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an
innovative biotechnology company focused on developing intellectual property relating to the treatment of
mental health and substance use disorders, and the co-development
of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on
trauma-related mental health disorders, such as PTSD, which
affected approximately 13 million adults in the U.S. in 2020, with
the Company estimating a current affected population of 20 million
across the US, UK and key EU markets.
For more information, please visit
www.graftpolymer.co.uk.
About Reach announcements
This is an RNS Reach announcement.
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM
Rules for Companies, Market Abuse Regulation or other regulation
would be disseminated as an RNS regulatory announcement and not on
Reach.